$KANT
KINETA, INC./DE Stock $kant

$kant Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-K Financial Statement

#000156459017005625 Filed on March 30, 2017

Income Statement

Concept	2015 Q4	2015 Q3	2015 Q2
Revenue	$1.234M	$1.201M	$1.070M
YoY Change	-6.52%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.770M	$1.520M	$1.710M
YoY Change	129.87%
% of Gross Profit
Research & Development	$5.787M	$6.258M	$5.976M
YoY Change	6.77%
% of Gross Profit
Depreciation & Amortization	$70.00K	$70.00K	$70.00K
YoY Change	-22.22%	-66.67%
% of Gross Profit
Operating Expenses	$7.556M	$7.781M	$7.685M
YoY Change	22.27%
Operating Profit	-$6.322M	-$6.580M	-$6.615M
YoY Change
Interest Expense	$0.00	$189.0K	$209.0K
YoY Change	-100.0%
% of Operating Profit
Other Income/Expense, Net	$691.0K	-$281.0K	$205.0K
YoY Change	263.68%
Pretax Income	-$5.630M	-$7.050M	-$6.620M
YoY Change	16.32%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$5.631M	-$7.050M	-$6.619M
YoY Change	16.34%
Net Earnings / Revenue	-456.32%	-587.01%	-618.6%
Basic Earnings Per Share	-$13.95	-$16.77	$0.12
Diluted Earnings Per Share	-$13.95	-$16.77	-$0.46
COMMON SHARES
Basic Shares Outstanding	569.0K	556.6K	553.5K
Diluted Shares Outstanding	569.0K	556.6K	14.52M

Balance Sheet

Concept	2015 Q4	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.84M	$20.90M
YoY Change	57.32%
Cash & Equivalents	$13.84M	$20.92M
Short-Term Investments	$0.00
Other Short-Term Assets	$180.0K	$300.0K
YoY Change	-55.0%
Inventory
Prepaid Expenses
Receivables	$918.0K	$1.200M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$14.94M	$22.40M
YoY Change	40.96%
LONG-TERM ASSETS
Property, Plant & Equipment	$566.0K	$600.0K
YoY Change	-5.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$144.0K	$2.300M
YoY Change	-76.0%
Total Long-Term Assets	$3.748M	$3.000M
YoY Change	212.33%
TOTAL ASSETS
Total Short-Term Assets	$14.94M	$22.40M
Total Long-Term Assets	$3.748M	$3.000M
Total Assets	$18.69M	$25.40M
YoY Change	58.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.330M	$3.900M
YoY Change	75.26%
Accrued Expenses	$2.248M	$2.000M
YoY Change	49.87%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.836M	$10.00M
YoY Change	63.93%
LONG-TERM LIABILITIES
Long-Term Debt	$100.0K	$200.0K
YoY Change	-99.03%
Other Long-Term Liabilities	$4.600M	$5.700M
YoY Change	24.32%
Total Long-Term Liabilities	$4.700M	$5.900M
YoY Change	-66.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.836M	$10.00M
Total Long-Term Liabilities	$4.700M	$5.900M
Total Liabilities	$14.50M	$15.90M
YoY Change	-27.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$120.2M
YoY Change
Common Stock	$1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$108.1M	$9.500M
YoY Change
Total Liabilities & Shareholders Equity	$18.69M	$25.40M
YoY Change	58.39%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2015 Q2
OPERATING ACTIVITIES
Net Income	-$5.631M	-$7.050M	-$6.619M
YoY Change	16.34%
Depreciation, Depletion And Amortization	$70.00K	$70.00K	$70.00K
YoY Change	-22.22%	-66.67%
Cash From Operating Activities	-$6.530M	-$6.300M	-$2.060M
YoY Change	123.63%	76.97%
INVESTING ACTIVITIES
Capital Expenditures	-$30.00K	-$210.0K	-$10.00K
YoY Change	0.0%	110.0%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities	-$30.00K	-$210.0K	-$10.00K
YoY Change	0.0%	110.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-520.0K	25.57M	-360.0K
YoY Change	-110.57%	393.63%
NET CHANGE
Cash From Operating Activities	-6.530M	-6.300M	-2.060M
Cash From Investing Activities	-30.00K	-210.0K	-10.00K
Cash From Financing Activities	-520.0K	25.57M	-360.0K
Net Change In Cash	-7.080M	19.06M	-2.430M
YoY Change	-459.39%	1153.95%
FREE CASH FLOW
Cash From Operating Activities	-$6.530M	-$6.300M	-$2.060M
Capital Expenditures	-$30.00K	-$210.0K	-$10.00K
Free Cash Flow	-$6.500M	-$6.090M	-$2.050M
YoY Change	124.91%	76.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2016	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2016	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25024042
CY2016Q2	dei	Entity Public Float EntityPublicFloat	126989176
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13844000
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	668000
CY2015Q4	pti	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	2744000
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	144000
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	294000
CY2015Q4	us-gaap	Assets Assets	18690000
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3330000
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2248000
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	4076000
CY2015Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	182000
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4265000
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	87000
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	287000
CY2015Q4	pti	Preferred Stock Warrant Liability PreferredStockWarrantLiability	110000
CY2016Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	91000
CY2016Q4	us-gaap	Liabilities Liabilities	9684000
CY2015Q4	us-gaap	Liabilities Liabilities	14500000
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	112292000
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	541000
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4089000
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33959000
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	472000
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	427000
CY2016	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-77000
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25000734
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25000734
CY2014	us-gaap	Operating Expenses OperatingExpenses	20833000
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	294000
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	566000
CY2016Q4	us-gaap	Assets Assets	91140000
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2021000
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4328000
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	68000
CY2016	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2016	dei	Trading Symbol TradingSymbol	PTI
CY2016	dei	Entity Registrant Name EntityRegistrantName	PROTEOSTASIS THERAPEUTICS, INC.
CY2016	dei	Entity Central Index Key EntityCentralIndexKey	0001445283
CY2016	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2016	dei	Document Type DocumentType	10-K
CY2016	dei	Amendment Flag AmendmentFlag	false
CY2016	dei	Document Period End Date DocumentPeriodEndDate	2016-12-31
CY2016	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18613000
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	66897000
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	918000
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4059000
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	180000
CY2016Q4	us-gaap	Assets Current AssetsCurrent	90237000
CY2015Q4	us-gaap	Assets Current AssetsCurrent	14942000
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2204000
CY2016Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	201000
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8754000
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9836000
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	752000
CY2014	us-gaap	Investment Income Interest InvestmentIncomeInterest	1000
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-37455000
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-24534000
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25040000
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11880000
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-15683000
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-22000
CY2015	us-gaap	Operating Expenses OperatingExpenses	28846000
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	246000
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37254000
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	109000
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15772000
CY2015Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2000
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2016	us-gaap	Operating Expenses OperatingExpenses	45839000
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16744000
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6322000
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22524000
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-37232000
CY2014	us-gaap	Interest Expense InterestExpense	199000
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	93000
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-15772000
CY2014	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	7837000
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	26000
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-22000
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-157450000
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-120218000
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	12115000
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	238902000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	81456000
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-108102000
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	91140000
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18690000
CY2016Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0
CY2015Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	110057398
CY2016Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0
CY2015Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	104854769
CY2016Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0
CY2015Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	104854769
CY2016Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	0
CY2015Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	149392000
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	571137
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	571137
CY2016	us-gaap	Revenues Revenues	8384000
CY2015	us-gaap	Revenues Revenues	4312000
CY2014	us-gaap	Revenues Revenues	5150000
CY2015	us-gaap	Interest Expense InterestExpense	599000
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-23000
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-25040000
CY2016	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	1378000
CY2015	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	9724000
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-38610000
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23309000
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29646000
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.06
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-42.14
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-63.74
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18759369
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	553162
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	465115
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-73726000
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	177000
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	274000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-95084000
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	95000
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	268000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1805000
CY2016	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	112292000
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	62000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	28000
CY2016	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	359000
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-22000
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	306000
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	272000
CY2016	pti	Premium On Short Term Investments PremiumOnShortTermInvestments	184000
CY2016	pti	Noncash Rent Expense Income NoncashRentExpenseIncome	-181000
CY2015	pti	Noncash Rent Expense Income NoncashRentExpenseIncome	-63000
CY2015	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	21090000
CY2014	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	4932000
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	268000
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	95000
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	177000
CY2015	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5000000
CY2014	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	10000000
CY2014	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	79000
CY2016	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3311000
CY2014	pti	Noncash Rent Expense Income NoncashRentExpenseIncome	423000
CY2015	us-gaap	Paid In Kind Interest PaidInKindInterest	599000
CY2014	us-gaap	Paid In Kind Interest PaidInKindInterest	199000
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	1805000
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	472000
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	274000
CY2016	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	359000
CY2016	pti	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	89000
CY2015	pti	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	-63000
CY2014	pti	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	-76000
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-82000
CY2015	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-10000
CY2014	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	80000
CY2016	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	13000
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-250000
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-506000
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1309000
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3871000
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-190000
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-84000
CY2016	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-76000
CY2015	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-182000
CY2014	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-26000
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-289000
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	361000
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1226000
CY2016	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2350000
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	498000
CY2014	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	7000
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-5385000
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2681000
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3134000
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-41925000
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-19415000
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8659000
CY2016	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	69812000
CY2016	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	3000000
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	229000
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	263000
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	172000
CY2016	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	13000
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-67028000
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-263000
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-172000
CY2016	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	46500000
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	70265000
CY2015	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1456000
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	113722000
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	24729000
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	15030000
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4769000
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5051000
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6199000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2594000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8793000
CY2015	pti	Conversion Of Convertible Promissory Notes And Accrued Interest Into Convertible Preferred Stock ConversionOfConvertiblePromissoryNotesAndAccruedInterestIntoConvertiblePreferredStock	15798000
CY2016	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	112292000
CY2016	pti	Stock Issued For Payment Of Accrued Dividends StockIssuedForPaymentOfAccruedDividends	3000
CY2016	pti	Stock Issued For Payment Of Accrued Bonus StockIssuedForPaymentOfAccruedBonus	62000
CY2016	pti	Conversion Of Preferred Stock Warrants To Common Stock Warrants ConversionOfPreferredStockWarrantsToCommonStockWarrants	28000
CY2016	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	60000
CY2015	pti	Deferred Offering Costs Included In Accounts Payable And Accrued Expense DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense	1288000
CY2016	us-gaap	Nature Of Operations NatureOfOperations	<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:5.24%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Nature of the Business </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proteostasis Therapeutics, Inc. (the “Company”) was incorporated in Delaware on December 13, 2006. The Company is an innovative biopharmaceutical company committed to the discovery and development of novel therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. The Company’s initial therapeutic focus is on cystic fibrosis, which is caused by defects in the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein and insufficient CFTR protein function. The Company’s lead product candidate, PTI-428, and its PTI-801 candidate, are in early clinical development, and the Company’s other drug candidates are in the preclinical development and discovery phase. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with ASC 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. As of December 31, 2016, the Company had an accumulated deficit of $157.5 million. During the year ended December 31, 2016, the Company incurred a loss of $37.2 million and used $41.9 million of cash in operations. The Company expects to continue to generate operating losses in the foreseeable future. The Company currently expects that its cash, cash equivalents and short-term investments of $85.5 million will be sufficient to fund its operating expenses and capital requirements, based upon its current operating plan, at least 12 months from the issuance date of these financial statements.<font style="font-size:12pt;"> </font>The future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its operations. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reverse Stock Split </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 19, 2016, the Company effected a 1-for-10.8102 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company’s Preferred Stock (see Note 9). Accordingly, all share and per share amounts for all periods presented in the accompanying financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split and adjustment of the preferred stock conversion ratios. </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Public Offerings </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the Company issued and sold 6,250,000 shares of its common stock in its initial public offering (“IPO”) at a public offering price of $8.00 per share, for net proceeds of $42.5 million after deducting underwriting discounts and commissions of $3.5 million and other offering expenses of $4.0 million. Upon the closing of the IPO, all shares of convertible preferred stock then outstanding converted into an aggregate of 9,699,600 shares of common stock, and the Company issued 2,590,742 shares of common stock as payment of $36.0 million of accruing dividends due to holders of Series A preferred stock. In addition, the Company’s convertible preferred stock warrant outstanding at the close of the IPO converted to a warrant to purchase common stock. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the completion of the IPO, the Company amended its certificate of incorporation to authorize the future issuance of up to 5,000,000 shares of undesignated preferred stock, par value $0.001 per share. As of December 31, 2016, there were no shares of preferred stock issued or outstanding.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2016, the Company issued and sold 5,750,000 shares of its common stock in a public offering at a public offering price of $13.00 per share, for net proceeds of $69.5 million after deducting underwriter discounts and commissions of $4.5 million and other offering expenses of $0.8 million. The foregoing includes the exercise by the underwriters of their options to purchase an additional 750,000 shares of our common stock within 30 days following the date of the final prospectus for the offering.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revision of Previously Issued Unaudited Quarterly Financial Data</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has revised Note 18 to correct errors in the reported amounts of basic net income per share attributable to common stockholders and diluted net loss per share attributable to common stockholders for the three months ended June 30, 2015 from the amounts appearing in the unaudited quarterly financial data footnote in the previously filed Form 10-K for the year ended December 31, 2015. Amounts previously reported for basic and diluted net income per share did not appropriately present the allocation of income to participating securities and reflect the impact of certain potential common shares. These revisions decreased basic net income attributable to common stockholders from $3.24 per share to $0.12 per share and reduced diluted net income attributable to common stockholders from $3.24 per share to a loss of $0.46 per share. Based upon the Company’s evaluation of relevant factors, the Company concluded that the revisions to the basic and diluted net income (loss) per share attributable to common stockholders as reflected in the unaudited quarterly footnote are not material to the previously issued quarterly financial data.</p></div>
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:5.24%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual for research and development expenses, including clinical trials, and the valuation of common stock, preferred stock warrant liability and derivative liability. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. </p></div>
CY2016	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Significant Customers </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:5.24%;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. The Company mitigates its risk with respect to cash, cash equivalents and short-term investments by maintaining its balances at two accredited financial institutions, in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company’s accounts receivable balances are due from counterparties to collaboration agreements (see Note 13) that the Company believes to be creditworthy. As of December 31, 2016 and 2015, accounts receivable consisted of amounts due from one and two such counterparties, respectively. </p></div>
CY2016	us-gaap	Property Plant And Equipment Impairment PropertyPlantAndEquipmentImpairment	<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:5.24%;">Long-lived assets consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. To date, the Company has not recorded any impairment losses on long-lived assets. </p></div>
CY2016	us-gaap	Derivatives Embedded Derivatives DerivativesEmbeddedDerivatives	<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Embedded Derivatives </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:5.24%;">Embedded derivatives that are required to be bifurcated from the underlying host instrument are accounted for and valued as a separate financial instrument. An embedded derivative exists associated with an alternate payment option upon change of control within the research, development and commercialization agreement with Cystic Fibrosis Foundation Therapeutics, Inc. (see Note 13). The embedded derivative has been bifurcated and is classified as a liability on the balance sheet and separately accounted for at its fair value. Changes in fair value of the derivative liability are recognized as a component of other income (expense), net in the statement of operations and comprehensive loss. </p></div>
CY2016	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On January 19, 2016, the Company effected a 1-for-10.8102 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company’s Preferred Stock
CY2016Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	10.8102
CY2016	pti	Stockholders Equity Reverse Stock Split Effective Date StockholdersEquityReverseStockSplitEffectiveDate	2016-01-19
CY2016Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	85500000
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.12
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2016Q4	pti	Number Of Accredited Financial Institutions NumberOfAccreditedFinancialInstitutions	2
CY2016Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	4000000
CY2016Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	800000
CY2015Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	66919000
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	22000
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	66897000
CY2016	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0
CY2016	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	0
CY2016Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2015Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2014Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2016Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2015Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2014Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2016Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2015Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2014Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2016Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2015Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2014Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2016	us-gaap	Fair Value Option Methodology And Assumptions FairValueOptionMethodologyAndAssumptions	Monte-Carlo simulation analysis
CY2016	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P2Y6M
CY2015	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P1M13D
CY2016	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.811
CY2015	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.741
CY2016	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0133
CY2015	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0014
CY2016	pti	Collaborative Arrangement Milestone Payment Expected CollaborativeArrangementMilestonePaymentExpected	28500000
CY2015	pti	Collaborative Arrangement Milestone Payment Expected CollaborativeArrangementMilestonePaymentExpected	28500000
CY2016	pti	Discount Rate Used To Derive Present Value Of Future Milestone Payments DiscountRateUsedToDerivePresentValueOfFutureMilestonePayments	0.25
CY2015	pti	Discount Rate Used To Derive Present Value Of Future Milestone Payments DiscountRateUsedToDerivePresentValueOfFutureMilestonePayments	0.25
CY2013Q4	pti	Preferred Stock Warrant Liability PreferredStockWarrantLiability	40000
CY2014Q4	pti	Preferred Stock Warrant Liability PreferredStockWarrantLiability	120000
CY2016	pti	Conversion Of Preferred Stock Warrants Into Common Stock Warrants ConversionOfPreferredStockWarrantsIntoCommonStockWarrants	28000
CY2013Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	141000
CY2014	pti	Fair Value Adjustment Of Derivative Liability FairValueAdjustmentOfDerivativeLiability	113000
CY2014	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	189000
CY2014Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	65000
CY2015	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	63000
CY2016	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-89000
CY2016Q4	pti	Prepaid Clinical Manufacturing And Scientific Expenses Current PrepaidClinicalManufacturingAndScientificExpensesCurrent	1390000
CY2016Q4	us-gaap	Prepaid Insurance PrepaidInsurance	104000
CY2015Q4	us-gaap	Prepaid Insurance PrepaidInsurance	39000
CY2016Q4	pti	Other Prepaid Expenses And Other Current Assets OtherPrepaidExpensesAndOtherCurrentAssets	2565000
CY2015Q4	pti	Other Prepaid Expenses And Other Current Assets OtherPrepaidExpensesAndOtherCurrentAssets	141000
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3864000
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3583000
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3323000
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3017000
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1813000
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1607000
CY2016Q4	pti	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	1612000
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	383000
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	520000
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	641000
CY2014Q3	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3700000
CY2014Q3	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1300000
CY2014Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5000000
CY2015Q3	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2017-01-31
CY2014Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	81760000
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016	us-gaap	Preferred Stock Dividend Payment Terms PreferredStockDividendPaymentTerms	In September 2015, in connection with the Series B preferred stock financing, (1) the right of the holders of Series A preferred stock to receive accruing dividends, whether or not declared, at a rate of 8.0% per year of the Original Issue Price per share (as described below) ceased as of August 31, 2015, at which time such cumulative accruing dividends totaled $36.0 million, and (2) the right of holders of Series A preferred stock to receive a cash payment of accruing dividends upon the automatic conversion of the Series A preferred stock into common stock was modified such that all previously accrued but unpaid dividends on Series A preferred stock will be paid in shares of common stock, at a price of $13.9019172 per share, upon such conversion of the Series A preferred stock. If as of January 1, 2016, the Series A preferred stock has not automatically converted into shares of common stock according to its terms, the holders of the Series A preferred stock will be entitled to receive dividends at the rate of 8.0% per year of the respective Original Issue Price per share, commencing as of the respective original issuance date of the Series A preferred stock. These amendments to the Series A preferred stock dividend rights were accounted for as a modification of preferred stock based on a quantitative assessment of the change in the fair value that resulted from the modification of the dividend rights on the modification date. The decrease in the fair value of Series A preferred stock measured immediately before the modification and immediately after the modification, equal to $0.2 million, was recorded as a deemed dividend from holders of preferred stock to the holders of common stock, resulting in an increase to additional paid-in capital of $0.2 million and a corresponding decrease of $0.2 to the carrying value of the Series A preferred stock.
CY2015	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	9699600
CY2016	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Each share of common stock entitles the holder to one vote for the election of directors and on all matters submitted to a vote of the Company’s stockholders.
CY2016	us-gaap	Dividends Dividends	0
CY2015	us-gaap	Dividends Dividends	0
CY2015Q2	pti	Increase Decrease In Share Based Compensation IncreaseDecreaseInShareBasedCompensation	-500000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0135
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0168
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0193
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M2D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M27D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y15D
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7319
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.5686
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.6016
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	979334
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1365230
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	101816
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	212231
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2030517
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1947267
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	518521
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.38
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.32
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.62
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.31
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.29
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.50
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.21
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M10D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y5M1D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y7M6D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y2M5D
CY2015Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	9141000
CY2016Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	10510000
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	9688000
CY2016Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	3757000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	400000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000
CY2016Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	5.47
CY2015Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	7.13
CY2014Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	1.91
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1100000
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	500000
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	200000
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2164000
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	472000
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	274000
CY2016Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	6600000
CY2016	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y11M27D
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340
CY2015Q2	us-gaap	Revenues Revenues	1070000
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.051
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.050
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.050
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.043
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.044
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.055
CY2014	pti	Effective Income Tax Rate Reconciliation Expiration Of Loss Carryforwards EffectiveIncomeTaxRateReconciliationExpirationOfLossCarryforwards	-0.024
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.005
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.012
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.011
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.429
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.422
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.410
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	53723000
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	39392000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	6633000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5015000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	2152000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	2155000
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	62508000
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	46562000
CY2016Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	66000
CY2015Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	86000
CY2016Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	66000
CY2015Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	86000
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	62442000
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	46476000
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	263200000
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	263200000
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	190700000
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	190700000
CY2016	pti	Tax Credit Carry Forward Began To Expiration TaxCreditCarryForwardBeganToExpiration	2026
CY2015	pti	Tax Credit Carry Forward Began To Expiration TaxCreditCarryForwardBeganToExpiration	2030
CY2016Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	7500000
CY2015Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5800000
CY2016	pti	Federal And State Research And Development Tax Credit Carryforward Expiration Beginning Year FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardExpirationBeginningYear	2027
CY2015	pti	Federal And State Research And Development Tax Credit Carryforward Expiration Beginning Year FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardExpirationBeginningYear	2025
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	15966000
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35914000
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	10562000
CY2016	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2045317
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13284476
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21961255
CY2016	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2018-05-31
CY2009Q1	pti	Monthly Base Rent MonthlyBaseRent	100000
CY2009Q1	pti	Annual Increase In Lease Payments AnnualIncreaseInLeasePayments	0.014
CY2009Q1	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	300000
CY2016	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1600000
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1600000
CY2015	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1700000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1344000
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5017000
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6615000
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6580000
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-522000
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	205000
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-281000
CY2015Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	691000
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-5740000
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-6619000
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-7050000
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-5631000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	563000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1907000
CY2016Q1	us-gaap	Revenues Revenues	1158000
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5976000
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6258000
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1321000
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1709000
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1523000
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	5824000
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	7781000
CY2016Q2	us-gaap	Revenues Revenues	1451000
CY2016Q3	us-gaap	Revenues Revenues	1715000
CY2016Q4	us-gaap	Revenues Revenues	4060000
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6876000
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7404000
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9218000
CY2016Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10461000
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2301000
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3115000
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3266000
CY2016Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3198000
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	9177000
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	10519000
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	12484000
CY2016Q4	us-gaap	Operating Expenses OperatingExpenses	13659000
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8019000
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9068000
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10769000
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-9599000
CY2016Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	20000
CY2016Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	36000
CY2016Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	190000
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	28000
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5000
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-38000
CY2016Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8000
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-7991000
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-9053000
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-10771000
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-9417000
CY2016Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	1378000
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9369000
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9053000
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10771000
CY2016Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9417000
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.87
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.47
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10766722
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19139183
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20073685
CY2016Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24975010
CY2015Q1	us-gaap	Revenues Revenues	807000
CY2015Q3	us-gaap	Revenues Revenues	1201000
CY2015Q4	us-gaap	Revenues Revenues	1234000
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4503000
CY2015Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5787000
CY2015Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1769000
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	7685000
CY2015Q4	us-gaap	Operating Expenses OperatingExpenses	7556000
CY2015Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-6322000
CY2015Q1	us-gaap	Interest Expense InterestExpense	201000
CY2015Q2	us-gaap	Interest Expense InterestExpense	209000
CY2015Q3	us-gaap	Interest Expense InterestExpense	189000
CY2015Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	2087000
CY2015Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	2152000
CY2015Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	2459000
CY2015Q4	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	3026000
CY2015Q2	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	1726000
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7827000
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	68000
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9336000
CY2015Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7940000
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-14.68
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-16.77
CY2015Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-13.95
CY2015Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	533097
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	553526
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	556567
CY2015Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	569026
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-14.68
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-16.77
CY2015Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-13.95
CY2015Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	533097
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14515998
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	556567
CY2015Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	569026

Files In Submission

Name	View Source	Status
0001564590-17-005625-index-headers.html	Edgar Link	pending
0001564590-17-005625-index.html	Edgar Link	pending
0001564590-17-005625.txt	Edgar Link	pending
0001564590-17-005625-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g2017033019170197254831.jpg	Edgar Link	pending
g2017033019170199154832.jpg	Edgar Link	pending
g2017033019170199254833.jpg	Edgar Link	pending
g2017033019170199354834.jpg	Edgar Link	pending
g2017033019170199454835.jpg	Edgar Link	pending
g2017033019170199654836.jpg	Edgar Link	pending
g2017033019170214054837.jpg	Edgar Link	pending
g2017033019170215554838.jpg	Edgar Link	pending
g2017033019170217354839.jpg	Edgar Link	pending
g2017033019170218454840.jpg	Edgar Link	pending
g2017033019170220354841.jpg	Edgar Link	pending
g2017033019170221554842.jpg	Edgar Link	pending
g2017033019170223154843.jpg	Edgar Link	pending
g2017033019171353554844.jpg	Edgar Link	pending
pti-10k_20161231.htm	Edgar Link	pending
pti-20161231.xml	Edgar Link	completed
pti-20161231.xsd	Edgar Link	pending
pti-20161231_cal.xml	Edgar Link	unprocessable
pti-20161231_def.xml	Edgar Link	unprocessable
pti-20161231_lab.xml	Edgar Link	unprocessable
pti-20161231_pre.xml	Edgar Link	unprocessable
pti-ex231_1017.htm	Edgar Link	pending
pti-ex311_355.htm	Edgar Link	pending
pti-ex312_354.htm	Edgar Link	pending
pti-ex321_353.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KANT
KINETA, INC./DE Stock $kant

2015 Q4 Form 10-K Financial Statement

#000156459017005625 Filed on March 30, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KANT KINETA, INC./DE Stock $kant

2015 Q4 Form 10-K Financial Statement

#000156459017005625 Filed on March 30, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KANT
KINETA, INC./DE Stock $kant